In this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects, evolution of the therapeutic regimen, from dapsone as a monotherapy to the proposed polychemotherapy by World Health Organization (WHO) can be found in this CME. We specifically highlight the drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification.
BT - Anais brasileiros de dermatologia C1 -http://www.ncbi.nlm.nih.gov/pubmed/29364430?dopt=Abstract
DO - 10.1590/abd1806-4841.20176724 IS - 6 J2 - An Bras Dermatol LA - eng N2 -In this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects, evolution of the therapeutic regimen, from dapsone as a monotherapy to the proposed polychemotherapy by World Health Organization (WHO) can be found in this CME. We specifically highlight the drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification.
PY - 2017 SP - 761 EP - 773 T2 - Anais brasileiros de dermatologia TI - Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients. UR - http://www.scielo.br/pdf/abd/v92n6/0365-0596-abd-92-06-0761.pdf VL - 92 SN - 1806-4841 ER -